Chardan Capital Reaffirms Buy Rating for Purple Biotech
| PPBT Stock | USD 2.22 0.02 0.89% |
Slightly above 62% of Purple Biotech's investor base is looking to short. The analysis of the overall investor sentiment regarding Purple Biotech suggests that many traders are alarmed. Purple Biotech's investing sentiment can be driven by a variety of factors including economic data, Purple Biotech's earnings reports, geopolitical events, and overall market trends.
Purple Biotech s stock had its buy rating restated by equities researchers at Chardan Capital in a research note issued on Thursday, Benzinga reports. They presently have a 11.00 target price on the stock. Chardan Capitals price target would indicate a potential upside of 496.21 percent from the companys previous close. Separately, HC
Read at thelincolnianonline.com
 |
Purple Biotech Fundamental Analysis
We analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Purple Biotech is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Purple Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Purple Biotech stock to make a market-neutral strategy. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics with similar companies.
Peers
Purple Biotech Related Equities
| PLUR | Pluri | 6.87 | ||||
| CING | Cingulate | 3.81 | ||||
| SLNO | Soleno Therapeutics | 2.14 | ||||
| SABS | SAB Biotherapeutics | 1.78 | ||||
| MNPR | Monopar Therapeutics | 0.83 | ||||
| PMVP | Pmv Pharmaceuticals | 1.12 | ||||
| ANEB | Anebulo Pharmaceuticals | 3.60 | ||||
| BLRX | BioLineRx | 3.66 | ||||
| ENLV | Enlivex Therapeutics | 4.55 | ||||
| CVKD | Cadrenal Therapeutics, | 4.73 |
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.